DRL launches nitroglycerin sublingual tablets in the US market

The Nitrostat (nitroglycerin) sublingual tablet brand had US sales of approximately $108 million MAT for the most recent twelve months ending in March 2016

Dr Reddy’s Laboratories (DRL) has launched nitroglycerin sublingual tablets USP, 0.3 mg, 0.4 mg and 0.6 mg, a therapeutic equivalent generic version of Nitrostat (nitroglycerin) sublingual tablets, in the US market after receiving United States Food & Drug Administration (USFDA) approval.

The Nitrostat (nitroglycerin) sublingual tablet brand had US sales of approximately $108 million MAT for the most recent twelve months ending in March 2016 according to IMS Health.

DRL’s Nitroglycerin sublingual tablets USP, 0.4 mg is available in bottle count size of 100 and a bundle of four bottles of count size 25, nitroglycerin sublingual tablets USP, 0.3mg is available in bottle count size of 100 and the nitroglycerin sublingual tablets USP, 0.6mg is available in bottle count size of 100.